IBJNews

Carmel's Dormir raises $12M from venture capital firms

Back to TopCommentsE-mailPrintBookmark and Share

Carmel-based Dormir Inc., which operates sleep study centers and sleep equipment stores around the country, raised $12 million in venture capital from three out-of-state firms.

The company plans use the proceeds to acquire six to 10 companies this year and more next year, according to CEO Tim Miller. Dormir is trying to scoop up financially weak sleep diagnostic and therapy companies.

Dormir already operates 32 sleep diagnostic centers and 31 retail stores. It acquired 12 of those locations earlier this year went it purchased two companies in Florida.

Dormir, which Miller launched in 2005, now employs 212, more than 80 of which are at its Carmel headquarters.

Dormir focuses on diagnosing patients with sleep apnea, which has been shown to contribute to numerous chronic diseases, such as hypertension.

"If we can bring these patients in and effectively treat them, we believe that we will save dollars to the health care system," Miller said.

Miller said he started to look for acquisitions after the federal Medicare program cut reimbursement for sleep therapy last fall, which has weakened many of his competitors. He said Dormir has continued to grow even after the reimbursement cuts.

The firm leading the investment round was Connecticut-based CHL Medical Partners. Also contributing were Georgia-based Noro-Moseley Partners and Massachusetts-based Excel Venture Management.

Miller declined to disclose Dormir's current revenue. However, he said he hopes to grow the company to 170 locations and more than $100 million in revenue by the end of 2012.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT